Pelthos Therapeutics (PTHS) Gross Margin (2025 - 2026)

Pelthos Therapeutics (PTHS) posted quarterly Gross Margin of 89.87% for Q4 2025, up 113.07% quarter-over-quarter from 687.76% in Q3 2025.

Pelthos Therapeutics (PTHS) Gross Margin (2025 - 2026) Analysis & Trends

Pelthos Therapeutics' Gross Margin history runs 1 years deep, the most recent figure standing at 89.87% for Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	85.33%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	91.59%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	90.43%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	35.86%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	89.76%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	76.90%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	84.20%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	63.27%
10	Pelthos Therapeutics	96.56 Mn	72.00 Mn	21.23 Mn	80.07%

Download Data